NASDAQ:GTHX - G1 Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $54.40
  • Forecasted Upside: 153.49 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.51 (2.43%)

This chart shows the closing price for GTHX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New G1 Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GTHX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GTHX

Analyst Price Target is $54.40
▲ +153.49% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for G1 Therapeutics in the last 3 months. The average price target is $54.40, with a high forecast of $82.00 and a low forecast of $21.00. The average price target represents a 153.49% upside from the last price of $21.46.

This chart shows the closing price for GTHX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in G1 Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2021Needham & Company LLCReiterated RatingBuy$68.00High
2/25/2021Needham & Company LLCLower Price TargetBuy$74.00 ➝ $68.00High
11/17/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$66.00 ➝ $21.00Medium
10/5/2020HC WainwrightReiterated RatingBuy$82.00Medium
8/20/2020WedbushReiterated RatingBuy$46.00Medium
8/18/2020HC WainwrightReiterated RatingBuy$82.00High
8/9/2020CowenReiterated RatingBuyHigh
8/6/2020WedbushLower Price TargetOutperform$50.00 ➝ $46.00High
8/3/2020Needham & Company LLCReiterated RatingBuy$74.00Medium
8/3/2020HC WainwrightReiterated RatingBuyMedium
7/1/2020Needham & Company LLCReiterated RatingBuy$74.00Medium
7/1/2020WedbushLower Price TargetOutperform$55.00 ➝ $50.00High
6/26/2020Roth CapitalInitiated CoverageBuy$55.00Medium
6/22/2020Needham & Company LLCReiterated RatingBuy$74.00Low
5/12/2020JPMorgan Chase & Co.Lower Price TargetOverweight$33.00 ➝ $23.00High
2/27/2020WedbushLower Price TargetOutperform$67.00 ➝ $55.00High
1/21/2020HC WainwrightReiterated RatingBuy$72.00 ➝ $82.00High
1/7/2020BTIG ResearchBoost Price TargetPositive ➝ Buy$51.00 ➝ $80.00Low
12/12/2019CowenReiterated RatingBuyHigh
12/12/2019Needham & Company LLCReiterated RatingBuy$74.00High
12/12/2019HC WainwrightReiterated RatingBuy$72.00High
11/6/2019CowenReiterated RatingBuyHigh
11/6/2019HC WainwrightReiterated RatingBuy$72.00High
9/30/2019Needham & Company LLCSet Price TargetBuy$74.00Low
9/30/2019CowenReiterated RatingBuyLow
9/30/2019HC WainwrightSet Price TargetBuy$72.00Low
9/27/2019B. RileySet Price TargetBuy$55.00Low
9/24/2019Needham & Company LLCSet Price TargetBuy$74.00Low
9/13/2019CowenReiterated RatingBuyHigh
9/11/2019HC WainwrightReiterated RatingBuy$72.00High
8/8/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$38.00 ➝ $45.00High
6/18/2019CowenReiterated RatingBuyHigh
6/2/2019CowenReiterated RatingBuyHigh
5/10/2019CowenReiterated RatingBuyHigh
3/6/2019CowenReiterated RatingBuyHigh
3/1/2019WedbushReiterated RatingOutperform$67.00High
2/7/2019B. RileyInitiated CoverageBuy ➝ Buy$55.00 ➝ $55.00Medium
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$59.00 ➝ $41.00High
12/21/2018CowenReiterated RatingBuyMedium
12/20/2018WedbushReiterated RatingOutperform$67.00High
12/19/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-BuyHigh
11/11/2018CowenReiterated RatingBuyHigh
11/8/2018Needham & Company LLCLower Price TargetBuy$76.00 ➝ $74.00High
9/18/2018Needham & Company LLCBoost Price TargetBuy$76.00High
9/17/2018HC WainwrightReiterated RatingBuy$79.00Low
9/10/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$80.00High
8/10/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$58.00 ➝ $63.00Low
8/9/2018CowenReiterated RatingBuyHigh
5/29/2018HC WainwrightInitiated CoverageBuy$61.00Medium
5/18/2018Needham & Company LLCBoost Price TargetBuy$42.00 ➝ $60.00High
3/13/2018Needham & Company LLCBoost Price TargetBuy$42.00High
3/7/2018BTIG ResearchReiterated RatingBuy$48.00High
3/6/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$33.00 ➝ $39.00High
3/5/2018CowenReiterated RatingBuyLow
2/22/2018BTIG ResearchReiterated RatingBuy$38.00High
2/5/2018JPMorgan Chase & Co.Boost Price Target$30.00High
12/19/2017BTIG ResearchInitiated CoverageBuy$38.00Low
11/8/2017CowenReiterated RatingBuyN/A
8/9/2017CowenReiterated RatingBuyLow
6/12/2017WedbushInitiated CoverageOutperform$31.00High
6/12/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$34.00High
6/12/2017CowenInitiated CoverageOutperform$31.00High
6/12/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$23.00High
(Data available from 6/21/2016 forward)
G1 Therapeutics logo
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Read More

Today's Range

Now: $21.46
Low: $20.73
High: $21.55

50 Day Range

MA: $21.79
Low: $19.57
High: $25.11

52 Week Range

Now: $21.46
Low: $10.81
High: $37.07


14,063 shs

Average Volume

1,315,735 shs

Market Capitalization

$902.91 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of G1 Therapeutics?

The following Wall Street research analysts have issued reports on G1 Therapeutics in the last twelve months: Cowen Inc, HC Wainwright, Needham & Company LLC, Raymond James, Roth Capital, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for GTHX.

What is the current price target for G1 Therapeutics?

5 Wall Street analysts have set twelve-month price targets for G1 Therapeutics in the last year. Their average twelve-month price target is $54.40, suggesting a possible upside of 159.7%. HC Wainwright has the highest price target set, predicting GTHX will reach $82.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $21.00 for G1 Therapeutics in the next year.
View the latest price targets for GTHX.

What is the current consensus analyst rating for G1 Therapeutics?

G1 Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GTHX will outperform the market and that investors should add to their positions of G1 Therapeutics.
View the latest ratings for GTHX.

What other companies compete with G1 Therapeutics?

How do I contact G1 Therapeutics' investor relations team?

G1 Therapeutics' physical mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company's listed phone number is 919-213-9835 and its investor relations email address is [email protected] The official website for G1 Therapeutics is